Two NSCLC patients harboring an Epidermal growth factor receptor (EGFR)_T790M mutation were treated with a single agent EGFR_T790M specific tyrosine kinase inhibitor [15] with differing clinical outcomes. Here, EGFR is linked to non-small cell lung carcinoma.